The designation for ALTO-101 targets cognitive impairment, a debilitating aspect of schizophrenia with no currently approved treatments.
H.C. Wainwright more than doubles its price target to $7 as the company delivers its first electrolyzer to a major green hydrogen facility in Portugal.
Investor demand drives prices to new all-time highs as Bitcoin balances on exchanges plummet to a six-year low.
Fiscal paralysis in Washington delays key economic data while the central bank cuts rates to support a cooling economy, creating a complex outlook for investors.
The U.S. Food and Drug Administration has accepted for review the company's New Drug Application for Relacorilant, a treatment for Cushing's syndrome.
Key approvals for Regeneron, Corcept, and a Fast Track designation for Alto Neuroscience signal a positive regulatory environment.
Analyst sets a new $70 price target, citing strong revenue forecasts and potential for margin expansion for the airline carrier.
Analyst cites a 'stronger for longer' demand cycle for hard disk drives, fueled by the explosive growth of cloud computing and AI.